Calibration of immunohistochemistry for assessment of HER2 in breast cancer: Results of the French Multicentre GEFPICS Study

Histopathology

Volumn 42, Issue 4, 2003, Pages 337-347

  Vincent Salomon, Anne ^a   MacGrogan, G ^b   Couturier, J ^a   Arnould, L ^c   Denoux, Y ^d   Fiche, M ^e   Jacquemier, J ^f   Mathieu, M C ^g   Penault Llorca, F ^h   Rigaud, C ⁱ   Roger, P ^j   Treilleux, I ^k   Vilain, M O ^l   Mathoulin Pelissier S ^b   Le Doussal, V ^m  

^a INSTITUT CURIE   (France)

^b INSTITUT BERGONIÉ   (France)

^c CENTRE GEORGES FRANÇOIS LECLERC   (France)

^d CENTRE FRANÇOIS BACLESSE   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f Department of Oncological Surgery   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h CENTRE JEAN PERRIN   (France)

ⁱ Institut Godinot   (France)

^j MONTPELLIER UNIVERSITY HOSPITAL   (France)

^k Centre L Berard   (France)

^l Centre O Lambret   (France)

^m CENTRE RENÉ HUGUENIN   (France)

more..

Author keywords

Breast cancer; Calibration; FISH; HER 2 neu; Herceptin; Immunohistochemistry; Quality control; Sensitivity; Specificity; Standardization

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; M PROTEIN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 0347539778     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2003.01598.x     Document Type: Article

References (29)

1. Couturier J, Vincent-Salomon A, Nicolas A et al. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod. Pathol. 2000; 13; 1238-1243.
2. Jacobs TW, Gown AM, Yaziji H et al. Specificity of HercepTest in determining HER2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J. Clin. Oncol. 1999: 17; 1983-1987.
3. Lebeau A, Deimling D, Kaltz C et al. HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J. Clin. Oncol. 2001; 19; 354-363.
4. Pauletti G, Dandekar S, Rong HM et al. Assessment of methods tissue-based detection of the HER-2/neu alteration in breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J. Clin. Oncol. 2000; 18: 3651-3664.
5. Roche P, Ingle JN. Increased HER2 with U.S. Food and Drug Administration-approved antibody. J. Clin. Oncol. 1999: 17; 434.
6. Maia DM. Immunohistochemical assays for HER2 overexpression. J. Clin. Oncol. 1999: 17; 1650.
7. Fitzgibbons PL, Page DL, Weaver D et al. Prognostic factors in breast cancer. College of American Pathologists consensus statement 1999. Arch. Pathol. Lab. Med. 2000: 124; 966-978.
8. Ellis IO, Dowsett M, Bartlett J et al. Recommendations for HER2 testing in the UK. J. Clin. Pathol. 2000: 53; 890-892.
9. Mass RD, Sanders C, Charlene K. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridisation (FISH) in the Herceptin pivotal trials. In Oncol PASC ed. ASCO 2000.
10. Kallioniemi O, Kallioniemi A, Kurisu W et al. ERBB2 amplification in breast cancer analysed by fluorescence in situ hybridization. Proc. Am. Soc. Clin. Oncol. 1992: 89; 5321-5325.
11. Persons DL, Borelli KA, Hsu PH. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod. Pathol. 1997: 10; 720-727.
12. Niehans GA, Singleton TP, Dykoski D et al. Stability of HER-2/neu expression over time and at multiple metastatic sites. J. Natl Cancer Inst. 1993; 85; 1230-1235.
13. Barnes DM, Lammie GA, Millis RR et al. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br. J. Cancer 1988; 58; 448-452.
14. Masood S, Bui MM. Assessment of Her2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann. Clin. Lab. Sci. 2000; 30; 259-265.
15. Vincent-Salomon A, Jouve M, Génin P et al. HER2 status in breast carcinomas not selectively modified by preoperative chemotherapy and stable during metastatic process. Cancer 2002: 94; 2169-2173.
16. Penault-Llorca F, Adelaide J, Houvenaeghel G et al. Optimization of immunohistochemical detection of ERBB2 in breast cancer: impact of fixation. J. Pathol. 1994: 173; 65-75.
17. Haerslev T, Jacobsen GK. Microwave processing of formalin-fixed and paraffin embedded sections improves the immunoreactivity of c-erbB-2 oncoprotein in breast carcinoma. Appl. Immunohistochem. 1993: 1; 223-226.
18. Press M, Hung G, Godolphin W et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994: 54; 2771-2777.
19. Lehr HA, Jacobs TW, Yaziji H et al. Quantitative evaluation of HER-2/neu status in breast cancers by fluorescence in situ hybridization and by immunohistochemistry with image analysis. Am. J. Clin. Pathol. 2001; 115; 814-822.
20. Gown AM, De Wever N, Battifora H. Microwave-based antigenic unmasking: a revolutionary new technique for routine immunohistochemistry. Appl. Immunohistochem. 1993; 1; 256-266.
21. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989: 244; 707-712.
22. Ridolfi R, Mehdi R, Jamehdor MD et al. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod. Pathol. 2000; 13; 866-873.
23. Hoang MP, Sahin AA, Ordonez NG et al. HER-2/neu gene amplification compared with HER2-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am. J. Clin. Pathol. 2000; 113; 852-859.
24. Tubbs RR, Pettay JD, Roche PC et al. Discrepancies in clinical laboratory testing of eligibility for Trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J. Clin. Oncol. 2001: 19; 2714-2721.
25. Jacobs T, Gown A, Yaziji H et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for evaluation of HER-2/neu in breast cancer. J. Clin. Oncol. 1999: 17; 1974-1982.
26. Thor A. Are patterns of HER-2/neu amplification and expression among primary tumors and regional metastases indicative of those in distant metastases and predictive of Herceptin response? J. Natl Cancer Inst. 2001; 93; 1120-1121.
27. Thor A, Liu S, Edgerton S et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J. Clin. Oncol. 2000; 18; 3230-3239.
28. Thor A. HER2-a discussion of testing approaches in the USA. Ann. Oncol. 2001; 12 (Suppl, 1); S101-S107.
29. Penault-Llorca F, Jacquemier J, Le Doussal V et al. Quality challenge for immunohistochemistry: example of the ERBB-2 status in breast cancer. Group for evaluation of prognostic factors in immunohistochemistry in breast cancer. Ann. Pathol. 1999; 19; 280-282.